未登录

D

Daniel A. Harki

University of Minnesota

H指数:31

被引数:3,551

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Development of a Real-Time Fluorescence-Based Deamination Assay and Identification of Inhibitors of Human Cytidine Deaminase

基于荧光的胞嘧啶脱氨酶实时脱氨检测方法的开发及人源胞嘧啶脱氨酶抑制剂的鉴定

ACS Chemical Biology

IF3.8

2025-10-220

PRE

A Novel Fluorescence Polarization Binding Assay for the Main Protease (Mpro) of SARS-CoV-2

一种针对SARS-CoV-2主要蛋白酶（Mpro）的新型荧光偏振结合分析

ACS Pharmacology & Translational Science

IF3.7

2025-10-140

OAAI

Targeting N-Myc in neuroblastoma with selective Aurora kinase A degraders

CELL CHEMICAL BIOLOGY

IF7.2

2025-02-010

OAAI

Identification of a novel allosteric binding site on the catalytic domain of NF-κB inducing kinase (NIK)

RSC MEDICINAL CHEMISTRY

IF3.6

2025-01-010

PRE

The Impact of Sugar Conformation on the Single-Stranded DNA Selectivity of APOBEC3A and APOBEC3B Enzymes

ACS CHEMICAL BIOLOGY

IF3.8

2024-12-160

PRE

A compact stem-loop DNA aptamer targets a uracil-binding pocket in the SARS-CoV-2 nucleocapsid RNA-binding domain

NUCLEIC ACIDS RESEARCH

IF13.1

2024-10-091

OAAI

Development of 3′-Deoxy-3′,4′-didehydro-nucleoside Prodrug Inhibitors of West Nile and Zika Viruses

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2024-07-151

PRE

Development of Allosteric NIK Ligands from Fragment-Based NMR Screening

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2023-11-034

PRE

Fragment-Based NMR Screening of the BPTF PHD Finger Methyl Lysine Reader Leads to the First Small-Molecule Inhibitors

BPTF PHD指甲基赖氨酸读取器的基于片段的NMR筛选导致第一个小分子抑制剂

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2023-10-034

PRE

Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding

NATURE COMMUNICATIONS

IF15.7

2023-06-0313

OAAI

Recent progress and structural analyses of domain-selective BET inhibitors

MEDICINAL RESEARCH REVIEWS

IF11.6

2023-03-2714

OA

APOBEC3A Catalytic Inactivity Mutation Induces Tertiary Structure Destabilization

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2023-02-145

OA

Interfering with nucleotide excision by the coronavirus 3′-to-5′ exoribonuclease

NUCLEIC ACIDS RESEARCH

IF13.1

2022-12-228

OAAI

Development of an N-Terminal BRD4 Bromodomain-Targeted Degrader

N-末端BRD4溴结构域靶向降解剂的研制

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2022-09-297

OA

Expanding Catch and Release DNA Decoy (CRDD) Technology with Pyrimidine Mimics

CHEMISTRY-A EUROPEAN JOURNAL

IF3.7

2022-08-250

OA

SARS-CoV-2 nsp14 Exoribonuclease Removes the Natural Antiviral 3′-Deoxy-3′,4′-didehydro-cytidine Nucleotide from RNA

IF3.5

2022-08-167

OAAI

Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 Mpro/3CLpro in Living Cells

IF4.7

2022-06-2822

OAAI

The current toolbox for APOBEC drug discovery

APOBEC药物发现的当前工具箱

TRENDS IN PHARMACOLOGICAL SCIENCES

IF19.9

2022-05-0116

OA

A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes

一种基于结构的高亲和力BRD4 D1-Selective化学探针的设计方法

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2022-01-1024

OA

Induced intra- and intermolecular template switching as a therapeutic mechanism against RNA viruses

IF16.6

2021-11-0111

OAAI